Part 1

Part 2

Part 3

Part 4

Part 5

The release of the 1-year results of the DRCRnet's Protocol T study were of great interest to the retina community. Some physicians saw the data as proof positive that certain disease indicators called for particular therapeutic approaches for DME patients. Others noted that although the data were interesting, 2 years of data were required to fully assess the efficacy of the tested anti-VEGF agents. Now that the 2-year data are released, how should retina specialists apply this new information in the clinic? Join our panel of research experts as they parse the 2-year Protocol T data, enabling you to provide the most effective care for your DME patients. Protocol Review:
A Discussion of Various Protocols and How They Affect Patient and Practice Management

Release Date: April 2016
Expiration Date: April 2017

Content Source

This continuing medical education (CME) activity captures from a webinar which was held in March of 2016.

Activity Description

The International Diabetes Federation predicts by 2035, more than 590 million people will be living with diabetes (up from the current estimate of 387 million). Others predict there will be closer to 600 million people with diabetes by 2035. Similarly, the number of people affected by vision-threatening diabetic retinopathy (DR) will rise in tandem.

As newer therapies enter the market, treatment options and dosing strategies can be impacted by the cost of treatment, which continues to be a major factor in treatment planning. As a result of these newer treatment options, the Diabetic Retinopathy Clinical Research Network ( has undertaken numerous research studies to further define the best treatment options for a variety of patient profiles. (The 2015 PAT survey indicated most retina specialists overwhelmingly (about 60%) would treat a young patient with both anti-VEGF and laser).

Clinicians using anti-VEGF treatments for DME need to update their knowledge in order to provide their patients with the best understanding of treatment expectations and minimization of risks. It is hoped the results from newly completed and still-ongoing studies from the groups will help achieve those goals.

Target Audience

This certified CME activity is designed for retina specialists and general ophthalmologists involved in the management of patients with retinal disease.

Learning Objectives

Upon completion of this activity, the participant should be able to:
   • Describe the current epidemiology of diabetic macular edema and diabetic retinopathy
   • Educate patients on the ophthalmic implications of systemic diabetes management
   • Assess clinical studies involving new approaches to treat DME
   • Use expert case examples to differentiate between clinical study dosing protocols and alternative dosing schedules
   • Evaluate treatment options and develop a treatment regimen that can reduce patient burden and practice capacity
   • Explain the early warning signs of elevated IOP
   • Identify effective management strategies for patients requiring intervention

Credit Designation Statement

Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Grantor Statement

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals, Inc.

Disclosure Policy Statement

It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical Education LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

Off-Label Statement

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC or Regeneron Pharmaceuticals, Inc.